A detailed history of Pathstone Holdings, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Pathstone Holdings, LLC holds 30,527 shares of PCVX stock, worth $2.62 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
30,527
Previous 28,373 7.59%
Holding current value
$2.62 Million
Previous $2.14 Million 62.7%
% of portfolio
0.02%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$70.52 - $117.12 $151,900 - $252,276
2,154 Added 7.59%
30,527 $3.49 Million
Q2 2024

Aug 14, 2024

BUY
$60.06 - $78.77 $306,306 - $401,727
5,100 Added 21.91%
28,373 $2.14 Million
Q1 2024

May 13, 2024

BUY
$59.79 - $81.05 $1.17 Million - $1.58 Million
19,516 Added 519.46%
23,273 $1.59 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $170,379 - $238,231
3,757 New
3,757 $235,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.09B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.